You are here: Controversies / David Janowsky: Cholinergic muscarinic mechanisms in depression and mania / Samuel Gershon’s further comment
Saturday, 18.09.2021

David Janowsky: Cholinergic muscarinic mechanisms in depression and mania

 

Samuel Gershon’s further comment

 

       I read this vast assembly  of material (Janowsky 2019) and find it to be encyclopedic and educational. However, we still have some of the basic questions unanswered. Yes, bio-transmitters in the brain (which ones?) actually are responsible for what? I ended my 2019 note on the discussion with Dave Janowsky asking this question after the presentation of the papers in that series.

       However, now I have a real discovery for all you readers to admire and scratch your heads – Brexpiprazole. This compound is approved in various  countries for the treatment of schizophrenia and MDD.

       Pay Attention: "…brexpiprazole is a serotonin-dopamine activity modulator that is a partial agonist at 5 HT1A  and Dopamine D2 receptors and an antagonist at 5 HT 2A and noradrenaline alpha 1b2C receptors all with  sub-nanomolar affinity” (McEvoy and Citrome 2016).

       Now, this is a brain twister; and people say we are not making any progress in psychopharmacology.

 

Reference:

Gershon S. Samuel Gershon’s opening comments. Cholinergic muscarinic mechanisms in depression and mania. inhn.org.controversies. October 10, 2019.

Janowsky D. David Janowsky: Cholinergic muscarinic mechanisms in depression and mania. inhn.org.controversies. September 12, 2019. 

McEvoy J, Citrome L. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator. Clin Schizophr Relat Psychoses, 2016;9(4):177-86.

 

May 13, 2021